JPRN-jRCT1061220067RecruitingPhase 2
Fracture prevention using selective estrogen receptor modulatorin patients with osteoporosis who received radiation therapy for cervical cancer - Frap-SERM
agao Shoji0 sites80 target enrollmentStarted: November 4, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- Female
Inclusion Criteria
- •Patients who meet all of the following criteria will be considered.
- •Patients with histologically confirmed cervical cancer.
- •Patients who are scheduled to receive radical radiotherapy, including concomitant intracavitary irradiation, as initial treatment for cervical cancer.
- •Postmenopausal patients ,menstrual amenorrhea for at least twelve months prior to the start of radiotherapy.
- •Patients who have given written consent to participate in the study.
Exclusion Criteria
- •Patients who are expected to have difficulty completing the study or subsequent follow-up, or who are deemed unsuitable by their physicians.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longitudinal phase 3 study.Most troublesome vulvovaginal atrophy symptomEUCTR2021-004536-28-SEppsala University, Department of Women's and Children´s Health120
Completed
Not Applicable
Clinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in Schizophreniacognitive deficits in patients with schizophreniapsychotic symptoms in patients with schizophreniaMental Health - SchizophreniaACTRN12608000461392niversity of New South Wales80
Terminated
Phase 2
Estrogen Patch for COVID-19 SymptomsCOVIDNCT04359329Sharon Nachman2
Completed
Early Phase 1
Raising Insulin Sensitivity in Post MenopauseMenopauseNCT02274571Pennington Biomedical Research Center8
Completed
Phase 4
Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal WomenRecurrent Urinary Tract InfectionNCT01958073University of California, San Diego35